Greetings from MyCancerHaven!
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
MonumenTAL-1 updates on talquetamab, a GPRC5D bispecific for RRMM.
Sequencing bispecific agents in the evolving multiple myeloma treatment landscape.
Evaluating teclistamab, daratumumab, and pomalidomide for multiple myeloma treatment.
CAR T in earlier lines: Updates from key clinical trials.
Dr. Rifkin reviews Dreamm-7 trial data in relapsed myeloma.
Dr. Landgren discusses Tocilizumab prophylaxis in relapsed/refractory myeloma.
Talquetamab step-up dosing strategies and CRS monitoring in treatment.
Myeloma, GVHD, NHL Updates: Drs Rajkumar, Farhadfar, and Smith
Increasing access to bispecific antibodies in relapsed/refractory multiple myeloma treatment.
Insights from recent research and trials shaping the future of myeloma care.
CAR T Therapy: Real-world financial and practical logistics explored.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
We wanted to update you on our recent activities.
Here are the latest posts last week:
Blogs :
MonumenTAL-1 updates on talquetamab, a GPRC5D bispecific for RRMM.
Sequencing bispecific agents in the evolving multiple myeloma treatment landscape.
Evaluating teclistamab, daratumumab, and pomalidomide for multiple myeloma treatment.
CAR T in earlier lines: Updates from key clinical trials.
Dr. Rifkin reviews Dreamm-7 trial data in relapsed myeloma.
Dr. Landgren discusses Tocilizumab prophylaxis in relapsed/refractory myeloma.
Talquetamab step-up dosing strategies and CRS monitoring in treatment.
Myeloma, GVHD, NHL Updates: Drs Rajkumar, Farhadfar, and Smith
Increasing access to bispecific antibodies in relapsed/refractory multiple myeloma treatment.
Insights from recent research and trials shaping the future of myeloma care.
CAR T Therapy: Real-world financial and practical logistics explored.
Also at MCH the News and Tweets never stop flowing!
Join Us at www.mycancerhaven.org
The Team @ MCH
Follow us on Facebook, Twitter (@My_Cancer_Haven), Instagram, YouTube, LinkedIn and TikTok
Note: Please do not reply to this e-mail as it is sent from an account that is not monitored. You can contact us by e-mail at contact@mycancerhaven.org.
